The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
The Yin and Yang of Toll-like receptors in cancer
Open accessAbstract
Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen-associated molecular patterns (PAMPs) but have also been implicated in the recognition of damage-associated molecular patterns (DAMPs). As such, TLRs regulate a wide range of biological responses including inflammatory and immune responses during carcinogenesis. The high expression of TLRs by antigen-presenting cells, including dendritic cells, and their ability to induce antitumor mediators such as type I interferon has led to efforts to utilize TLR agonists in tumor therapy in order to convert the often tolerant immune response toward antitumor responses. However, TLRs are also increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor survival signals. Here, we will review in detail the dichotomous role of TLRs in tumor biology, focusing on relevant TLR-dependent pro- and antitumor pathways, and discuss clinical applications of TLR-targeted therapies for tumor prevention and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
CA: A Cancer Journal for Clinicians
(2010) · CA A Cancer Journal for Clinicians · doi:10.3322/(issn)1542-4863 · Cited by 2,538
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationTumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
Signaling in innate immunity and inflammation
Newton, K., & Dixit, V. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006049 · Cited by 1,513
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., Lovat, F., Fadda, P., Mao, C., Nuovo, G. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209414109 · Cited by 1,434
Regulation of lung injury and repair by Toll-like receptors and hyaluronan
Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G. D., Mascarenhas, M. M., Garg, H. G., Quinn, D. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1315 · Cited by 1,401
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Self-citationAutoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.
Asano, M., Toda, M., Sakaguchi, N., & Sakaguchi, S. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.387 · Cited by 1,330
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327
Rifaximin Treatment in Hepatic Encephalopathy
Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R. J., Patterson, C. J., Tripsas, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,294
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Maeda, S., Kamata, H., Luo, J.-L., Leffert, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,164
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Böhle, A., Palou-Redorta, J., & Rouprêt, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.017 · Cited by 1,067
Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors
Morales, A. (1976) · The Journal of Urology · Cited by 978
Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121343109 · Cited by 974
Targeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
Cross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882
Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis
Popivanova, B. K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., Oshima, M., Fujii, C., & Mukaida, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32453 · Cited by 832
Hall, M. C., Chang, S. S., Dalbagni, G., Pruthi, R. S., Seigne, J. D., Skinner, E. C., Wolf, J. S., & Schellhammer, P. F. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.09.003 · Cited by 830
Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S., Penz-Oesterreicher, M., Bjorkdahl, O., Fox, J. G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.011 · Cited by 813
Mitochondrial reactive oxygen species drive proinflammatory cytokine production
Naik, E., & Dixit, V. M. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110367 · Cited by 783
GENETIC ANALYSIS OF HOST RESISTANCE: Toll-Like Receptor Signaling and Immunity at Large
Beutler, B., Jiang, Z., Georgel, P., Crozat, K., Croker, B., Rutschmann, S., Du, X., & Hoebe, K. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090552 · Cited by 772
Apoptosis and cancer: the genesis of a research field
Cotter, T. G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2663 · Cited by 758
Ballas, Z. K., Rasmussen, W. L., & Krieg, A. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.1840 · Cited by 754
Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell Function
Peng, G., Guo, Z., Kiniwa, Y., Voo, K. S., Peng, W., Fu, T., Wang, D. Y., Li, Y., Wang, H. Y., & Wang, R.-F. (2005) · Science · doi:10.1126/science.1113401 · Cited by 746
Trinchieri, G., & Santoli, D. (1978) · The Journal of experimental medicine · doi:10.1084/jem.147.5.1314 · Cited by 733
An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
Burdelya, L. G., Krivokrysenko, V. I., Tallant, T. C., Strom, E., Gleiberman, A. S., Gupta, D., Kurnasov, O. V., Fort, F. L., Osterman, A. L., DiDonato, J. A., et al. (2008) · Science · doi:10.1126/science.1154986 · Cited by 705
Paik, Y.-H., Schwabe, R. F., Bataller, R., Russo, M. P., Jobin, C., & Brenner, D. A. (2003) · Hepatology · doi:10.1053/jhep.2003.50182 · Cited by 651
Self-citationLotze, M. T., Zeh, H. J., Rubartelli, A., Sparvero, L. J., Amoscato, A. A., Washburn, N. R., DeVera, M. E., Liang, X., Tör, M., & Billiar, T. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00579.x · Cited by 641
CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
Hartmann, G., Weiner, G. J., & Krieg, A. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9305 · Cited by 626
Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors
Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.008 · Cited by 621
SIGIRR, a negative regulator of Toll-like receptor–interleukin 1 receptor signaling
Wald, D., Qin, J., Zhao, Z., Qian, Y., Naramura, M., Tian, L., Towne, J., Sims, J. E., Stark, G. R., & Li, X. (2003) · Nature Immunology · doi:10.1038/ni968 · Cited by 606
Pull, S. L., Doherty, J. M., Mills, J. C., Gordon, J. I., & Stappenbeck, T. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405979102 · Cited by 605
Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88
Rakoff-Nahoum, S., & Medzhitov, R. (2007) · Science · doi:10.1126/science.1140488 · Cited by 584
NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer
Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R., Huot, L., Grandjean, T., Bressenot, A., Delanoye-Crespin, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62236 · Cited by 572
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Tumour immunity: effector response to tumour and role of the microenvironment
Mantovani, A., Romero, P., Palucka, A. K., & Marincola, F. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60241-x · Cited by 537
Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
Trinchieri, G. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075008 · Cited by 511
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 494
Sakurai, T., He, G., Matsuzawa, A., Yu, G.-Y., Maeda, S., Hardiman, G., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.016 · Cited by 487
Rowland, I. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.281 · Cited by 469
Fukata, M., Chen, A., Klepper, A., Krishnareddy, S., Vamadevan, A. S., Thomas, L. S., Xu, R., Inoue, H., Arditi, M., Dannenberg, A. J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.017 · Cited by 455
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
The Rel/NF-κB signal transduction pathway: introduction
Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203237 · Cited by 433
Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands
West, X. Z., Malinin, N. L., Merkulova, A. A., Tischenko, M., Kerr, B. A., Borden, E. C., Podrez, E. A., Salomon, R. G., & Byzova, T. V. (2010) · Nature · doi:10.1038/nature09421 · Cited by 431
Salcedo, R., Worschech, A., Cardone, M., Jones, Y., Gyulai, Z., Dai, R.-M., Wang, E., Ma, W., Haines, D., O'hUigin, C., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100199 · Cited by 429
Development of TLR9 agonists for cancer therapy
Krieg, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31414 · Cited by 429
Current insights into the regulation of programmed cell death by NF-κB
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gélinas, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209938 · Cited by 407
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
Lofgren, J. L., Whary, M. T., Ge, Z., Muthupalani, S., Taylor, N. S., Mobley, M., Potter, A., Varro, A., Eibach, D., Suerbaum, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.048 · Cited by 381
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Gibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00517-8 · Cited by 375
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., & Stingl, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070021 · Cited by 363
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349
Activation of Innate Immunity Is Required for Efficient Nuclear Reprogramming
Lee, J., Sayed, N., Hunter, A., Au, K. F., Wong, W. H., Mocarski, E. S., Pera, R. R., Yakubov, E., & Cooke, J. P. (2012) · Cell · doi:10.1016/j.cell.2012.09.034 · Cited by 344
Human lung cancer cells express functionally active Toll-like receptor 9
Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A. J., Branscheid, D., Vollmer, E., Dalhoff, K., Zabel, P., & Goldmann, T. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-1 · Cited by 340
Xiao, H., Gulen, M. F., Qin, J., Yao, J., Bulek, K., Kish, D., Altuntas, C. Z., Wald, D., Ma, C., Zhou, H., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.02.012 · Cited by 324
Synbiotics in Health and Disease
Kolida, S., & Gibson, G. R. (2011) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-022510-133739 · Cited by 309
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Swann, J. B., Vesely, M. D., Silva, A., Sharkey, J., Akira, S., Schreiber, R. D., & Smyth, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708594105 · Cited by 308
Ochi, A., Nguyen, A. H., Bedrosian, A. S., Mushlin, H. M., Zarbakhsh, S., Barilla, R., Zambirinis, C. P., Fallon, N. C., Rehman, A., Pylayeva-Gupta, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111706 · Cited by 304
De Palma, M., Mazzieri, R., Politi, L. S., Pucci, F., Zonari, E., Sitia, G., Mazzoleni, S., Moi, D., Venneri, M. A., Indraccolo, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.09.004 · Cited by 301
NF‐κB and cancer: Mechanisms and targets
Karin, M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20217 · Cited by 298
TLR7 and TLR8 as targets in cancer therapy
Schön, M. P., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 296
Fiebiger, E., Maurer, D., Holub, H., Reininger, B., Hartmann, G., Woisetschläger, M., Kinet, J. P., & Stingl, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118325 · Cited by 294
Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M., & Sibilia, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61034 · Cited by 294
Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review
Love, W. E., Bernhard, J. D., & Bordeaux, J. S. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.291 · Cited by 287
Starnes, C. O. (1992) · Nature · doi:10.1038/357011a0 · Cited by 284
Zhang, H.-L., Yu, L.-X., Yang, W., Tang, L., Lin, Y., Wu, H., Zhai, B., Tan, Y.-X., Shan, L., Liu, Q., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.011 · Cited by 281
Kadowaki, N., Antonenko, S., & Liu, Y.-J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2291 · Cited by 280
Pierer, M., Rethage, J., Seibl, R., Lauener, R., Brentano, F., Wagner, U., Hantzschel, H., Michel, B. A., Gay, R. E., Gay, S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.1256 · Cited by 273
STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation
Tye, H., Kennedy, C. L., Najdovska, M., McLeod, L., McCormack, W., Hughes, N., Dev, A., Sievert, W., Ooi, C. H., Ishikawa, T.-O., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.010 · Cited by 273
Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9
Watanabe, A., Hashmi, A., Gomes, D. A., Town, T., Badou, A., Flavell, R. A., & Mehal, W. Z. (2007) · Hepatology · doi:10.1002/hep.21867 · Cited by 262
Tumor Promotion via Injury- and Death-Induced Inflammation
Kuraishy, A., Karin, M., & Grivennikov, S. I. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.006 · Cited by 261
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Intestinal myofibroblasts in innate immune responses of the intestine
Otte, J.-M., Rosenberg, I. M., & Podolsky, D. K. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00403-7 · Cited by 242
Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy?
Apte, R. N., & Voronov, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00615.x · Cited by 239
Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M.-C., Fridman, W.-H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36551 · Cited by 237
Wounding and Its Role in RSV-Mediated Tumor Formation
Dolberg, D. S., Hollingsworth, R., Hertle, M., & Bissell, M. J. (1985) · Science · doi:10.1126/science.2996144 · Cited by 230
Csak, T., Velayudham, A., Hritz, I., Petrasek, J., Levin, I., Lippai, D., Catalano, D., Mandrekar, P., Dolganiuc, A., Kurt-Jones, E., et al. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00163.2009 · Cited by 229
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue, N., & Seya, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113099109 · Cited by 224
Merrell, M. A., Ilvesaro, J. M., Lehtonen, N., Sorsa, T., Gehrs, B., Rosenthal, E., Chen, D., Shackley, B., Harris, K. W., & Selander, K. S. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0007 · Cited by 223
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Zbar, B., & Tanaka, T. (1971) · Science · doi:10.1126/science.172.3980.271 · Cited by 217
Fort, M. M., Mozaffarian, A., Stöver, A. G., Correia, J. D. S., Johnson, D. A., Crane, R. T., Ulevitch, R. J., Persing, D. H., Bielefeldt-Ohmann, H., Probst, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6416 · Cited by 216
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N., & Van Tendeloo, V. F. I. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0097 · Cited by 215
Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., & Zhang, D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1993 · Cited by 214
Cubillos-Ruiz, J. R., Engle, X., Scarlett, U. K., Martinez, D., Barber, A., Elgueta, R., Wang, Nesbeth, Y., Durant, Gewirtz, A. T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37716 · Cited by 208
Le Leu, R. K., Hu, Y., Brown, I. L., Woodman, R. J., & Young, G. P. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp197 · Cited by 206
Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APC Min/+ mice
Li, Y., Kundu, P., Seow, S. W., de Matos, C. T., Aronsson, L., Chin, K. C., Kärre, K., Pettersson, S., & Greicius, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs137 · Cited by 206
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans
Ochi, A., Graffeo, C. S., Zambirinis, C. P., Rehman, A., Hackman, M., Fallon, N., Barilla, R. M., Henning, J. R., Jamal, M., Rao, R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63606 · Cited by 199
Fukata, M., Shang, L., Santaolalla, R., Sotolongo, J., Pastorini, C., España, C., Ungaro, R., Harpaz, N., Cooper, H. S., Elson, G., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21527 · Cited by 199
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20696 · Cited by 195
Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer
Sfondrini, L., Rossini, A., Besusso, D., Merlo, A., Tagliabue, E., Mènard, S., & Balsari, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6624 · Cited by 194
Heckelsmiller, K., Rall, K., Beck, S., Schlamp, A., Seiderer, J., Jahrsdörfer, B., Krug, A., Rothenfusser, S., Endres, S., & Hartmann, G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3892 · Cited by 194
Yu, P., Lübben, W., Slomka, H., Gebler, J., Konert, M., Cai, C., Neubrandt, L., Prazeres da Costa, O., Paul, S., Dehnert, S., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.07.018 · Cited by 192
TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells
Mittal, D., Saccheri, F., Vénéreau, E., Pusterla, T., Bianchi, M. E., & Rescigno, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.94 · Cited by 192
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier, A. F., Chen, L., Maltonti, F., & Delattre, J. (1999) · PubMed · Cited by 185
Rhee, S. H., Im, E., & Pothoulakis, C. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.022 · Cited by 183
Sha, T., Sunamoto, M., Kitazaki, T., Sato, J., Ii, M., & Iizawa, Y. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.027 · Cited by 178
Cornell, R. P., Liljequist, B. L., & Bartizal, K. F. (1990) · Hepatology · doi:10.1002/hep.1840110603 · Cited by 178
Seki, E., Tsutsui, H., Iimuro, Y., Naka, T., Son, G., Akira, S., Kishimoto, T., Nakanishi, K., & Fujimoto, J. (2005) · Hepatology · doi:10.1002/hep.20603 · Cited by 173
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Sidky, Y. A., Borden, E. C., Weeks, C. E., et al. (1992) · PubMed · Cited by 169
Goldszmid, R. S., & Trinchieri, G. (2012) · Nature Immunology · doi:10.1038/ni.2422 · Cited by 166
Fukata, M., Hernandez, Y., Conduah, D. E., Cohen, J., Chen, A., Breglio, K. J., Goo, T., Hsu, D. S., Xu, R., & Abreu, M. T. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20880 · Cited by 161
Lowe, E. L., Crother, T. R., Rabizadeh, S., Hu, B., Wang, H., Chen, S., Shimada, K., Wong, M. H., Michelsen, K. S., & Arditi, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013027 · Cited by 160
Wound Healing Is Impaired in MyD88-Deficient Mice
Macedo, L., Pinhal‐Enfield, G., Alshits, V., Elson, G., Cronstein, B. N., & Leibovich, S. J. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061048 · Cited by 158
Regulation of wound healing and organ fibrosis by toll-like receptors
Huebener, P., & Schwabe, R. F. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.017 · Cited by 154
Self-citationBong, A. B., Bonnekoh, B., Franke, I., Schön, M. P., Ulrich, J., & Gollnick, H. P. M. (2002) · Dermatology · doi:10.1159/000063904 · Cited by 152
Garaude, J., Kent, A., van Rooijen, N., & Blander, J. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002868 · Cited by 147
Reddy, B. S., Weisburger, J. H., Narisawa, T., & Wynder, E. L. (1974) · PubMed · Cited by 144
The application of Toll like receptors for cancer therapy
So, E. Y., & Ouchi, T. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.675 · Cited by 144
Topical Imiquimod in the Treatment of Metastatic Melanoma to Skin
Wolf, I. H. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.3.273 · Cited by 141
Zbar, B., Bernstein, I., Tanaka, T., & Rapp, H. J. (1970) · Science · doi:10.1126/science.170.3963.1217 · Cited by 136
Tumor fibroblast–derived epiregulin promotes growth of colitis-associated neoplasms through ERK
Neufert, C. F., Becker, C., Türeci, Ö., Waldner, M. J., Backert, I., Floh, K., Atreya, I., Leppkes, M., Jefremow, A., Vieth, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63748 · Cited by 134
LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice
Isayama, F., Hines, I. N., Kremer, M., Milton, R. J., Byrd, C. L., Perry, A. W., McKim, S. E., Parsons, C., Rippe, R. A., & Wheeler, M. D. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00405.2005 · Cited by 123
Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.
Baines, J., & Celis, E. (2003) · PubMed · Cited by 122
Targeting pattern recognition receptors in cancer immunotherapy
Goutagny, N., Estornes, Y., Hasan, U. A., Lebecque, S., & Caux, C. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0213-1 · Cited by 121
Campbell, J. S., Riehle, K. J., Brooling, J. T., Bauer, R. L., Mitchell, C., & Fausto, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2522 · Cited by 118
IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis
Cataisson, C., Salcedo, R., Hakim, S., Moffitt, A. B., Wright, L. N., Yi, M., Stephens, R. M., Dai, R., Lyakh, L. A., Schenten, D., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20101355 · Cited by 116
Pandey, S., Mittal, R. D., Srivastava, M., Srivastava, K., Singh, S., Srivastava, S., & Mittal, B. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.032 · Cited by 114
Nierkens, S., den Brok, M. H., Garcia, Z., Togher, S., Wagenaars, J. A. L., Wassink, M., Boon, L., Ruers, T. J. M., Figdor, C. G., Schoenberger, S. P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2154 · Cited by 114
Arslan, F., Houtgraaf, J. H., Keogh, B., Kazemi, K., de Jong, R., McCormack, W. J., O'Neill, L. A. J., McGuirk, P., Timmers, L., Smeets, M. B., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.967596 · Cited by 113
Bekierkunst, A., Levij, I. S., Yarkoni, E., Vilkas, E., & LEDERER, E. (1971) · Science · doi:10.1126/science.174.4015.1240 · Cited by 113
Chin, A. I., Miyahira, A. K., Covarrubias, A. J., Teague, J., Guo, B., Dempsey, P. W., & Cheng, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1162 · Cited by 113
Lin, H., Yan, J., Wang, Z., Hua, F., Yu, J., Sun, W., Li, K., Liu, H., Yang, H., Lv, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25991 · Cited by 106
TREATMENT OF INOPERABLE MALIGNANT TUMORS WITH THE TOXINES OF ERYSIPELAS AND THE BACILLUS PRODIGIOSUS
COLEY, W. B. (1894) · The American Journal of the Medical Sciences · doi:10.1097/00000441-189407000-00006 · Cited by 104
Ebihara, T., Azuma, M., Oshiumi, H., Kasamatsu, J., Iwabuchi, K., Matsumoto, K., Saito, H., Taniguchi, T., Matsumoto, M., & Seya, T. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091573 · Cited by 101
Imiquimod in the treatment of lentigo maligna
Rajpar, S. F., & MARSDEN, J. R. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07476.x · Cited by 99
Chew, V., Tow, C., Huang, C. W., Bard-Chapeau, E. A., Copeland, N. G., Jenkins, N. A., Weber, A., Lim, K. H., Toh, H. C., Heikenwälder, M. F., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs436 · Cited by 92
Angiotensin II Upregulates Toll-Like Receptor 4 on Mesangial Cells
Wolf, G., Bohlender, J. M., Bondeva, T., Roger, T., Thaiss, F., & Wenzel, U. O. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070699 · Cited by 91
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue
Rossignol, D. P., & Lynn, M. (2002) · Journal of Endotoxin Research · doi:10.1179/096805102125001127 · Cited by 88
Impact of Toll-like receptor 4 polymorphisms on risk of cancer
Kutikhin, A. G. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.11.003 · Cited by 85
Bauer, A. K., Dixon, D., DeGraff, L. M., Cho, H., Walker, C. R., Malkinson, A. M., & Kleeberger, S. R. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji403 · Cited by 84
Paik, Y., Lee, K. S., Lee, H. J., Yang, K. M., Lee, S. J., Lee, D. K., Han, K., Chon, C. Y., Lee, S. I., Moon, Y. M., et al. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700422 · Cited by 81
Use of murine embryonic fibroblasts to define Toll-like receptor activation and specificity
Kurt‐Jones, E. A., Sandor, F., Ortiz, Y., Bowen, G. N., Counter, S. L., Wang, T. C., & Finberg, R. W. (2004) · Journal of Endotoxin Research · doi:10.1179/096805104225006516 · Cited by 79
Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs
Hasan, U. A., Caux, C., Perrot, I., Doffin, A., Ménétrier‐Caux, C., Trinchieri, G., Tommasino, M., & Vlach, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700664104 · Cited by 79
Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell
Ren, T., Wen, Z.-K., Liu, Z.-M., Liang, Y.-J., Guo, Z., & Xu, L. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4826 · Cited by 78
Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma
Brignole, C., Marimpietri, D., Paolo, D. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1251 · Cited by 77
Minmin, S., Xiaoqian, X., Hao, C., Baiyong, S., Deng, X., Jun-jie, X., Xi, Z., Jianquan, Z., & Songyao, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019466 · Cited by 76
Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8
Lan, T., Kandimalla, E. R., Yu, D. S., Bhagat, L., Li, Y., Wang, D., Zhu, F., Tang, J. X., Putta, M. R., Cong, Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706059104 · Cited by 75
Yusuf, N., Nasti, T. H., Long, J., Naseemuddin, M., Lucas, A. P., Xu, H., & Elmets, C. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5219 · Cited by 72
Significant association between toll-like receptor gene polymorphisms and gallbladder cancer
Srivastava, K., Srivastava, A., Kumar, A., & Mittal, B. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02268.x · Cited by 68
Wang, Z., Yan, J., Lin, H., Hua, F., Wang, X., Liu, H., Lv, X., Yu, J., Mi, S., Wang, J., et al. (2013) · Hepatology · doi:10.1002/hep.26234 · Cited by 65
Silencing of TLR4 Increases Tumor Progression and Lung Metastasis in a Murine Model of Breast Cancer
Ahmed, A., Wang, J. H., & Redmond, H. P. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2595-9 · Cited by 64
TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo
Ren, T., Xu, L., Jiao, S.-X., Wang, Y.-Y., Cai, Y.-Y., Liang, Y.-J., Zhou, Y., Zhou, H., & Wen, Z. (2009) · Pathology and Oncology Research · doi:10.1007/s12253-009-9162-0 · Cited by 61
Victories and deceptions in tumor immunology
Kroemer, G., Zitvogel, L., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23687 · Cited by 54
Anticancer TLR agonists on the ropes
Guha, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3775 · Cited by 53
Bourquin, C., Schmidt, L., Lanz, A.-L., Storch, B., Wurzenberger, C., Anz, D., Sandholzer, N., Mocikat, R., Berger, M., Poeck, H., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901594 · Cited by 43
Biologic activities of natural and synthetic type I interferons.
Pfeffer, L. M. (1997) · PubMed · Cited by 41
Reddy, B. S., & Watanabe, K. (1978) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/61.5.1269 · Cited by 40
Cell mediated immune responses through TLR4 prevents DMBA‐induced mammary carcinogenesis in mice
Naseemuddin, M., Iqbal, A., Nasti, T. H., Ghandhi, J. L., Kapadia, A. A., & Yusuf, N. (2011) · International Journal of Cancer · doi:10.1002/ijc.26100 · Cited by 37
Damiano, V., Garofalo, S., Rosa, R., Bianco, R., Caputo, R., Gelardi, T., Merola, G., Racioppi, L., Garbi, C., Kandimalla, E. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1599 · Cited by 37
Li, Y., Teo, W. L., Low, M., Meijer, L., Sanderson, I. R., Pettersson, S., & Greicius, G. (2013) · Oncogene · doi:10.1038/onc.2012.581 · Cited by 24
Cited by
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Self-citationObesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Metadata
- Authors
- Pradere, J.-P., Dapito, D. H., & Schwabe, R. F.
- Venue
- Oncogene
- Published
- 2013-08-12
- Volume
- 33
- Issue
- 27
- Pages
- 3485-3495
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2015649564
- Cited by
- 331
- References
- 184
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.